Abstract: A container can be used for growing a plant having roots. The container can comprise a rectangular sheet having an upper edge, a lower edge, a first side edge and a second side edge. The first side edge and the second side edge are joined forming a cylinder. The upper edge is configured to rest above a ground surface such that vertical root growth is substantially uninhibited by the container above the ground surface. An inward contoured lip can be formed into the lower edge. The rectangular sheet from the upper edge to the inward contoured lip constrains lateral growth of the roots of the plant above the ground surface while vertical root growth is completely uninhibited by the container below the inward contoured lip.

Abstract: A foldable lighted tree assembly includes an assembly frame with a plurality of elongated assembly frame legs each having a first leg end and a second leg end. The plurality of assembly frame legs converges at the second leg end. The plurality of assembly frame legs are selectively deployable between an extended, functional configuration wherein the assembly frame is generally pyramid-shaped and a folded, non-functional transport and storage configuration wherein the plurality of assembly frame legs are generally parallel and adjacent to each other. At least one light string having a plurality of lights is supported by the assembly frame.

Abstract: A downhole tool, a retrievable bridge plug system, and a method. The downhole tool includes a release mandrel, a plurality of slips disposed at least partially around the release mandrel, an upper cone disposed at least partially around the release mandrel and on a first axial side of the plurality of slips, a lower cone disposed at least partially around the outer mandrel and on a second axial side of the plurality of slips, and a collet positioned axially and radially between the release mandrel and the lower cone. The collet is configured to prevent downward movement of the lower cone relative to the release mandrel at least when the downhole tool is in a run-in configuration and when the downhole tool is in a set configuration.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: A downhole tool, a retrievable bridge plug system, and a method. The downhole tool includes a release mandrel, a plurality of slips disposed at least partially around the release mandrel, an upper cone disposed at least partially around the release mandrel and on a first axial side of the plurality of slips, a lower cone disposed at least partially around the outer mandrel and on a second axial side of the plurality of slips, and a collet positioned axially and radially between the release mandrel and the lower cone. The collet is configured to prevent downward movement of the lower cone relative to the release mandrel at least when the downhole tool is in a run-in configuration and when the downhole tool is in a set configuration.

Abstract: The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: A system and method for producing thermal spray coatings on a substrate from a liquid suspension is disclosed. The disclosed system and method include a thermal spray torch for generating a plasma and a liquid suspension delivery subsystem for delivering a flow of liquid suspension with sub-micron particles to the plasma to produce a plasma effluent. The liquid suspension delivery subsystem comprises an injector or nozzle which can produce an inert or reactive gas sheath partially or fully surrounding the plasma effluent. A sheath can also be used to isolate injection of the liquid suspension. A gas assist stream can also be employed at or near the suspension injection point. The shroud, sheath or gas assist technique can retain the sub-micron particles entrained within the plasma effluent and substantially prevent entrainment of ambient gases into the plasma effluent.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.

Abstract: Methods and systems for processing signals to minimize the effects of dye crosstalk. Deconvolution of multiplexed dye signals can include corrections for residual error determined from experimental measurements. Residual error corrections can account for reaction or assay specific factors and modify the subsequent filtering of signals. Correction values can be determined for specific dye-probe conjugates to minimize dye crosstalk and may be combined with residual error correction to further minimize errors in spectral deconvolution. Apparatus, systems, and computer-readable media can process signals and modify filters based on values obtained using the methods.

Abstract: Disclosed is a compound of the formula: and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered in combination with at least one addition pharmaceutically active ingredient.

Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.

Abstract: Methods and systems for processing signals to minimize the effects of dye crosstalk. Deconvolution of multiplexed dye signals can include corrections for residual error determined from experimental measurements. Residual error corrections can account for reaction or assay specific factors and modify the subsequent filtering of signals. Correction values can be determined for specific dye-probe conjugates to minimize dye crosstalk and may be combined with residual error correction to further minimize errors in spectral deconvolution. Apparatus, systems, and computer-readable media can process signals and modify filters based on values obtained using the methods.

Abstract: Disclosed is a compound of the formula: and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered in combination with at least one addition pharmaceutically active ingredient.

Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.

Abstract: In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein, methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.

Abstract: Disclosed are methods and compositions that may be used for purifying antibodies.